Gert Riethmuller
Overview
Explore the profile of Gert Riethmuller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
2838
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Banaszek A, Bumm T, Nowotny B, Geis M, Jacob K, Wolfl M, et al.
Nat Commun
. 2019 Nov;
10(1):5387.
PMID: 31772172
T cell-engaging immunotherapies are changing the landscape of current cancer care. However, suitable target antigens are scarce, restricting these strategies to very few tumor types. Here, we report on a...
2.
Kirak O, Riethmuller G
J Allergy Clin Immunol
. 2015 Apr;
136(3):800-802.e3.
PMID: 25825213
No abstract available.
3.
Krupka C, Kufer P, Kischel R, Zugmaier G, Bogeholz J, Kohnke T, et al.
Blood
. 2013 Dec;
123(3):356-65.
PMID: 24300852
Antibody-based immunotherapy represents a promising strategy to target and eliminate chemoresistant leukemic cells. Here, we evaluated the CD33/CD3-bispecific T cell engaging (BiTE) antibody (AMG 330) for its suitability as a...
4.
Lubben W, Turqueti-Neves A, Okhrimenko A, Stoberl C, Schmidt V, Pfeffer K, et al.
Eur J Immunol
. 2013 Feb;
43(5):1231-42.
PMID: 23423996
Immunoglobulin E (IgE) production is tightly regulated at the cellular and genetic levels and is believed to be central to allergy development. At least two cellular pathways exist that lead...
5.
Topp M, Gokbuget N, Zugmaier G, Degenhard E, Goebeler M, Klinger M, et al.
Blood
. 2012 Oct;
120(26):5185-7.
PMID: 23024237
Persistence or recurrence of minimal residual disease (MRD) after chemotherapy results in clinical relapse in patients with acute lymphoblastic leukemia (ALL). In a phase 2 trial of B-lineage ALL patients...
6.
7.
Topp M, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al.
J Clin Oncol
. 2011 May;
29(18):2493-8.
PMID: 21576633
Purpose: Blinatumomab, a bispecific single-chain antibody targeting the CD19 antigen, is a member of a novel class of antibodies that redirect T cells for selective lysis of tumor cells. In...
8.
Munz M, Murr A, Kvesic M, Rau D, Mangold S, Pflanz S, et al.
Cancer Cell Int
. 2010 Nov;
10:44.
PMID: 21044305
Background: Epithelial cell adhesion molecule (EpCAM) is frequently and highly expressed on human carcinomas. The emerging role of EpCAM as a signalling receptor and activator of the wnt pathway, and...
9.
Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al.
Science
. 2008 Aug;
321(5891):974-7.
PMID: 18703743
Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the...
10.
Husemann Y, Geigl J, Schubert F, Musiani P, Meyer M, Burghart E, et al.
Cancer Cell
. 2008 Jan;
13(1):58-68.
PMID: 18167340
It is widely accepted that metastasis is a late event in cancer progression. Here, however, we show that tumor cells can disseminate systemically from earliest epithelial alterations in HER-2 and...